Alkem Laboratories Limited Q2 FY27 Results Awaited as Board Meets

On 12 November 2026, Alkem Laboratories Limited is scheduled to approve Q2 FY27 results for the quarter ended 30 September, following Q1 FY27 revenue growth of 10.95% year on year to ₹3,740.15 crore. The September-quarter figures had not been filed with the NSE in the material provided, making the June-quarter performance the latest confirmed benchmark.

When will Alkem Laboratories release Q2 FY27 results?

Alkem Laboratories is scheduled to consider and approve its unaudited standalone and consolidated results for Q2 FY27 and the half year ended 30 September 2026 at a board meeting on Thursday, 12 November 2026. The company had informed the exchanges about the meeting on 4 November, according to the material provided.

The results cover the July-September 2026 period. At the time covered by the source material, the figures had not appeared on the NSE. The eventual filing is expected to set out revenue, profitability and earnings per share for both the quarter and the first half of FY27.

An earnings call was also scheduled for 12 November from 4:30 pm to 5:30 pm IST, hosted by Motilal Oswal Securities. That forum may provide management commentary on domestic pharmaceutical demand, overseas operations, input costs and operating margins, but no such commentary was available in the provided material before the results announcement.

What was Alkem Laboratories' latest reported quarterly performance?

Alkem Laboratories reported consolidated revenue from operations of ₹3,740.15 crore in Q1 FY27, compared with ₹3,371.14 crore in Q1 FY26, a year-on-year increase of 10.95%. Revenue was also 3.80% higher than ₹3,603.32 crore reported in the March 2026 quarter.

Total income for the June 2026 quarter was ₹3,892.90 crore, against ₹3,507.63 crore a year earlier and ₹3,803.39 crore in the preceding quarter. The company reported net profit for the period of ₹520.98 crore and net profit attributable to owners of ₹519.96 crore. Basic earnings per share stood at ₹43.49.

The comparison base matters because reported profit was lower than the ₹667.91 crore net profit recorded in Q1 FY26 and below the ₹653.03 crore reported in Q3 FY26. The source material described the Q1 FY27 decline in profit as approximately 22% year on year, even as revenue expanded.

Which Q2 FY27 metrics will investors watch most closely?

Investors will watch whether Alkem Laboratories sustains growth in its domestic branded formulations business and how its international operations contribute to consolidated revenue. The material identifies domestic pharmaceutical sales, international business performance, raw-material costs and operating profitability as the main areas under scrutiny.

The company had guided for its India business to grow 100-150 basis points above the Indian pharmaceutical market in FY27. The supplied preview stated that Alkem Laboratories delivered 13.2% India growth in Q1 FY27 versus 12.2% for the Indian pharmaceutical market, a 100-basis-point spread. The Q2 data will show whether that relative performance continued.

Profit conversion will be equally important because the latest quarter combined sales growth with a year-on-year fall in net profit. Investors can compare the reported September-quarter profit, margin disclosures and EPS with the June-quarter net profit of ₹520.98 crore and basic EPS of ₹43.49 once the filing becomes available.

How does the pending result affect Alkem Laboratories investors?

The pending result leaves investors without a confirmed September-quarter financial update as of the information supplied. The company was shown with a market capitalisation above ₹65,139 crore, but the material does not provide a share-price movement linked to the forthcoming results. Therefore, no stock-market reaction can be established from the available data.

For investors, the immediate significance is that Q2 results will update the company’s first-half FY27 financial position. Revenue growth in Q1 FY27 was supported by a higher June-quarter sales base than a year earlier, while profit was below the corresponding quarter. The new filing will provide the factual basis for assessing whether this divergence persisted, narrowed or changed direction.

The announcement also has relevance for the pharmaceutical sector because Alkem Laboratories' India business is described as a major contributor to consolidated revenue. Its disclosed comparison with Indian pharmaceutical market growth gives investors one measure of relative domestic execution, although the source does not provide Q2 sector-wide data or a final Q2 company comparison.

Conclusion

Alkem Laboratories enters its Q2 FY27 result announcement after reporting ₹3,740.15 crore in Q1 FY27 revenue, up 10.95% year on year, alongside net profit of ₹520.98 crore. The available information confirms the board meeting date and the latest reported financial benchmark, but does not include the September-quarter outcome.

The next item to watch is the NSE filing following the 12 November board meeting, including standalone and consolidated revenue, net profit, EPS and management commentary for the quarter and half year ended 30 September 2026. Investors will also look for an update on India-business growth relative to the broader pharmaceutical market and on the factors affecting profitability.